ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,00%
Dow Jones
39 387,76
0,85%
DAX
18 679,71
0,00%
Brent Oil
84,305
0,42%
Bitcoin
63 123,06
0,12%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) Actualités

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:BMY
DateHeureSourceTitreSymboleSociété
07/05/202412h59Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
06/05/202412h59Business WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...NYSE:BMYBristol Myers Squibb Co
06/05/202412h59Business WireU.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
01/05/202414h00GlobeNewswire Inc.Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell CollaborationNYSE:BMYBristol Myers Squibb Co
29/04/202412h00PR Newswire (US)Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune DiseasesNYSE:BMYBristol Myers Squibb Co
26/04/202412h59Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
25/04/202413h53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNYSE:BMYBristol Myers Squibb Co
25/04/202412h59Business WireBristol Myers Squibb Reports First Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
23/04/202413h25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:BMYBristol Myers Squibb Co
22/04/202412h59Business WireBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, FasterNYSE:BMYBristol Myers Squibb Co
08/04/202417h30Business WireKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)NYSE:BMYBristol Myers Squibb Co
06/04/202419h15Business WireBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
06/04/202419h15Business Wire Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research SocietyNYSE:BMYBristol Myers Squibb Co
05/04/202415h05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNYSE:BMYBristol Myers Squibb Co
03/04/202402h08Business WireEuropean Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)NYSE:BMYBristol Myers Squibb Co
02/04/202412h59Business WireBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term GoalsNYSE:BMYBristol Myers Squibb Co
28/03/202421h05Business WireBristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…NYSE:BMYBristol Myers Squibb Co
28/03/202421h01Business WireBristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s DiseaseNYSE:BMYBristol Myers Squibb Co
28/03/202412h30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsNYSE:BMYBristol Myers Squibb Co
26/03/202419h25Business WireA Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de SaúdeNYSE:BMYBristol Myers Squibb Co
26/03/202411h59Business WireBristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health OutcomesNYSE:BMYBristol Myers Squibb Co
25/03/202413h00Business WireBristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular PortfolioNYSE:BMYBristol Myers Squibb Co
20/03/202421h45Business WireBristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple MyelomaNYSE:BMYBristol Myers Squibb Co
20/03/202411h59Business WireBristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular CarcinomaNYSE:BMYBristol Myers Squibb Co
19/03/202411h59Business WireBristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” CampaignNYSE:BMYBristol Myers Squibb Co
18/03/202413h44Business WireBristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience PortfolioNYSE:BMYBristol Myers Squibb Co
15/03/202423h27Business WireFDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyNYSE:BMYBristol Myers Squibb Co
15/03/202402h35Business WireU.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)NYSE:BMYBristol Myers Squibb Co
11/03/202421h16Business WireBristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024NYSE:BMYBristol Myers Squibb Co
07/03/202420h23Business WireU.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Dernières Valeurs Consultées

EU
ACA
Credit Agricole
EU
SGO
Cie de SaintGobain
EU
BNP
BNP Paribas
NYSE
MRK
Merck
EU
LR
Legrand
EU
AF
Air FranceKLM
EU
VIV
Vivendi
EU
RI
Pernod Ricard
EU
MC
Lvmh Moet Hennessy Louis...
EU
ML
Michelin
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés